image dons

I make a donation

ATLANTIC

Multicentric international randomized trial aiming to evaluate the impact of using a prehospital loading dose of Ticagrelor versus intra-hospital use in treatment of acute myocardial infarct with ST segment elevation and treated by primary angioplasty

Terminée

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

logo étude

objectif

Prehospital ticagrelor in ST-segment elevation myocardial infarction.

date de réalisation

2011

nombre de patients

1858

nombre de centres participants

112 centers in 13 countries

type de financement

Private (AstraZeneca)

Référence

NCT01347580

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI) (ATLANTIC)

Study Description

The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention (PCI) and optimizing the outcome for the patient.
The study will assess the efficacy and safety of pre-hospital compared to in-hospital administration of ticagrelor in co-administration with aspirin, on restoring the blood flow in the occluded heart artery and improving the myocardial perfusion in patients suffering from myocardial infarction and planned to have a PCI. Patients can be randomised in either one of the 2 arms :

  • re-hospital ticagrelor arm: Patients will receive a loading dose of 180 mg ticagrelor for the pre-hospital administration and placebo for in-hospital administration.
  • or In-hospital ticagrelor arm: Patients will receive a placebo for pre-hospital administration and 180 mg ticagrelor loading dose for in-hospital administration.

Patients are initially managed by ambulance physician/personnel in pre hospital settings. They are then transferred into a Catheterization room to undergo a PCI. After the administration of the loading dose of ticagrelor (double blind), patients will continue on ticagrelor 90 mg bid and be followed in study for 30 days post randomisation.

source clinicaltrials.gov

Publications

  • Prehospital ticagrelor in ST-segment elevation myocardial infarction
    Gilles Montalescot, Arnoud W van 't Hof, Frédéric Lapostolle, Johanne Silvain, Jens Flensted Lassen, Leonardo Bolognese, Warren J Cantor, Angel Cequier, Mohamed Chettibi, Shaun G Goodman, Christopher J Hammett, Kurt Huber, Magnus Janzon, Béla Merkely, Robert F Storey, Uwe Zeymer, Olivier Stibbe, Patrick Ecollan, Wim M J M Heutz, Eva Swahn, Jean-Philippe Collet, Frank F Willems, Caroline Baradat, Muriel Licour, Anne Tsatsaris, Eric Vicaut, Christian W Hamm, ATLANTIC Investigators
    Publicated in The New England Journal of Medecine
  • Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction : ATLANTIC-Morphine
    Frédéric Lapostolle, Arnoud W Van't Hof, Christian W Hamm, Olivier Stibbe, Patrick Ecollan, Jean-Philippe Collet, Johanne Silvain, Jens Flensted Lassen, Wim M J M Heutz, Leonardo Bolognese, Warren J Cantor, Angel Cequier, Mohamed Chettibi, Shaun G Goodman, Christopher J Hammett, Kurt Huber, Magnus Janzon, Béla Merkely, Robert F Storey, Jur Ten Berg, Uwe Zeymer, Muriel Licour, Anne Tsatsaris, Gilles Montalescot, ATLANTIC Investigators
    Publicated in American Journal of Cardiovascular Drugs
  • Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty : A sub-analysis of the ATLANTIC trial
    Enrico Fabris, Arnoud Van't Hof, Christian W Hamm, Frédéric Lapostolle, Jens Flensted Lassen, Shaun G Goodman, Jurriën M Ten Berg, Leonardo Bolognese, Angel Cequier, Mohamed Chettibi, Christopher J Hammett, Kurt Huber, Magnus Janzon, Béla Merkely, Robert F Storey, Uwe Zeymer, Warren J Cantor, Mathieu Kerneis, Abdourahmane Diallo, Eric Vicaut, Gilles Montalescot, ATLANTIC investigators
    Publicated in Catheterization & Cardiovascular Interventions
  • Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction : Insights from the ATLANTIC study
    Akshay Bagai, Shaun G Goodman, Warren J Cantor, Eric Vicaut, Leonardo Bolognese, Angel Cequier, Mohamed Chettibi, Christopher J Hammett, Kurt Huber, Magnus Janzon, Frédéric Lapostolle, Jens Flensted Lassen, Béla Merkely, Robert F Storey, Jurriën M Ten Berg, Uwe Zeymer, Abdourahmane Diallo, Christian W Hamm, Anne Tsatsaris, Jad El Khoury, Arnoud W Van't Hof, Gilles Montalescot
    Publicated in American Heart Journal
  • Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction : Findings from the ATLANTIC trial
    Sinem Kilic, Enrico Fabris, Arnoud W J Van't Hof, Christian W Hamm, Frédéric Lapostolle, Jens Flensted Lassen, Anne Tsatsaris, Abdourahmane Diallo, Eric Vicaut, Gilles Montalescot, ATLANTIC Investigators
    Publicated in American Heart Journal
  • Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population
    Guillaume Cayla, Frédéric Lapostolle, Patrick Ecollan, Olivier Stibbe, Jean Francois Benezet, Patrick Henry, Christopher J Hammett, Jens Flensted Lassen, Robert F Storey, Jur M Ten Berg, Christian W Hamm, Arnoud W Van't Hof, Gilles Montalescot, ACTION study group
    Publicated in International Journal of Cardiology
  • P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study
    Johanne Silvain, Robert F Storey, Guillaume Cayla, Jean-Baptiste Esteve, Jean-Guillaume Dillinger, Hélène Rousseau, Anne Tsatsaris, Caroline Baradat, Néjoua Salhi, Christian W Hamm, Frédéric Lapostolle, Jens Flensted Lassen, Jean-Philippe Collet, Jurriën M Ten Berg, Arnoud W Van't Hof, Gilles Montalescot
    Publicated in Thrombosis and Haemostasis
  • Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H24 Analysis
    Gilles Montalescot, Arnoud W van 't Hof, Leonardo Bolognese, Warren J Cantor, Angel Cequier, Mohamed Chettibi, Jean-Philippe Collet, Shaun G Goodman, Christopher J Hammett, Kurt Huber, Magnus Janzon, Frédéric Lapostolle, Jens Flensted Lassen, Muriel Licour, Béla Merkely, Néjoua Salhi, Johanne Silvain, Robert F Storey, Jurriën M Ten Berg, Anne Tsatsaris, Uwe Zeymer, Eric Vicaut, Christian W Hamm, ATLANTIC Investigators
    Publicated in JACC: Cardiovascular Interventions
  • Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction : rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study
    Gilles Montalescot, Jens Flensted Lassen, Christian W Hamm, Frédéric Lapostolle, Johanne Silvain, Jurriën M ten Berg, Warren J Cantor, Shaun G Goodman, Muriel Licour, Anne Tsatsaris, Arnoud W van't Hof
    Publicated in American Heart Journal

Presentations

  • ESC2017 - Poster 'Thrombus aspiration ATLANTIC Trial'
    powerpoint pdf
  • ESC2017 - Poster 'ST-segment resolution ATLANTIC Trial'
    powerpoint pdf
  • ESC2016 - Poster 'ST-resolution ATLANTIC Study'
    pdf

Autres études

+

ACORES-2

En cours


Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.
+

ANCHOR

En cours


Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients
+

AFLOAT

En cours


To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.